FOR IMMEDIATE RELEASE

Weekly emails to hospital C-suite halt two decades of superbug outbreak

Washington, DC, April 28, 2014 – Efforts to reduce and stop the spread of infections caused by a highly resistant organism, carbapenem-resistant Acinetobacter baumannii, at a large Florida hospital proved ineffective until they added another weapon – weekly emails from the medical director of Infection Control to hospital leadership, according to a study published in the May issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).

When the hospital added the step of sending comprehensive weekly reports to physician, hospital nursing, medical, and administrative leadership, the rate of A. baumannii transmission decreased by 63 percent, according to the research team from the University of Miami Miller School of Medicine. Prior to this, endemic rates of A. baumannii had been present at the institution for nearly two decades.

“These regular highly visible communications allowed us to create a sense of accountability for new cases that unified both the leadership and providers toward the common goal of decreasing new acquisitions of carbapenem-resistant A. baumannii,” state the study authors.

The study analyzed a 42-month period of hospital data (January 1, 2010 to June 30, 2013) representing 1.1 million patient days. During Phase 1 (2010-2011), the bundle of interventions had been implemented but rates had not changed. During Phase 2 (2011-2012), the medical director of Infection Control sent weekly emails to hospital leadership describing and interpreting the surveillance results from the previous week, including the number and location of newly discovered isolates; results of environmental cultures obtained from bed rails, bedside tables, intravenous pumps, and nursing stations; and a map indicating the location of carbapenem-resistant A. baumannii positive patients and objects. Two intensive care units (ICUs) with the highest rates received daily emails. During Phase 3 (2012-2013), the bundle of interventions continued but the weekly emails ceased because there were only scattered weekly acquisitions. Overall acquisition of new cases of carbapenem-resistant A. baumannii decreased from 5.13 per 10,000 patient days in Period 1, to 1.93 in Period 3.

“These weekly emails not only packaged information on the number and locations of new acquisitions of A. baumannii, but also described and explained the results of environmental initiatives, hand culture results, and identification of shared objects among patients,” add the authors. “Additionally, these communications advised the hospital and each ICU’s leaders about the infection control data and provided action plans based on the findings.”

The bundle of infection prevention measures included 1) patient screening tests upon admission to the ICU and weekly thereafter; 2) isolation and separation of patients testing positive for A.
**baumannii;** 3) weekly sampling of surfaces in the hospital environment to assess thoroughness of cleaning; 4) hand hygiene interventions, including random cultures of healthcare workers’ hands, the results of which were included in the weekly reports; 5) observing shared objects that moved from patient-to-patient; and 6) monthly multidisciplinary meetings to discuss all issues related to implementing the bundle.

The authors conclude, “This is the first study to examine the effect of mass electronic dissemination of results from a bundle of interventions. Weekly electronic communications were associated with a striking decrease in the rate of new acquisitions of *A. baumannii* at our institution probably because of a combination of education, communication, feedback, and peer pressure.”

*Acinetobacter baumannii* is a type of gram-negative bacteria that is resistant to most antibiotics and has become one of the most worrisome and frequent organisms causing healthcare-associated infections in U.S. healthcare facilities.

Infections from *A. baumannii* occur mainly in intensive care units and affect primarily very ill, wounded, or immunocompromised patients. The germ can remain on wet or dry surfaces for longer than most other organisms, making it harder to eradicate. Multidrug-resistant *Acinetobacter* is classified as a serious threat by the Centers for Disease Control and Prevention.

**ABOUT AJIC: AMERICAN JOURNAL OF INFECTION CONTROL**

*AJIC: American Journal of Infection Control* ([www.ajicjournal.org](http://www.ajicjournal.org)) covers key topics and issues in infection control and epidemiology. Infection preventionists, including physicians, nurses, and epidemiologists, rely on *AJIC* for peer-reviewed articles covering clinical topics as well as original research. As the official publication of APIC, *AJIC* is the foremost resource on infection control, epidemiology, infectious diseases, quality management, occupational health, and disease prevention. *AJIC* also publishes infection control guidelines from APIC and the CDC. Published by Elsevier, *AJIC* is included in MEDLINE and CINAHL.

**ABOUT APIC**

*APIC*’s mission is to create a safer world through prevention of infection. The association’s more than 15,000 members direct infection prevention programs that save lives and improve the bottom line for hospitals and other healthcare facilities. *APIC* advances its mission through patient safety, implementation science, competencies and certification, advocacy, and data standardization. Visit APIC online at [www.apic.org](http://www.apic.org). Follow APIC on Twitter: [http://twitter.com/apic](http://twitter.com/apic) and Facebook: [www.facebook.com/APICInfectionPreventionandYou](http://www.facebook.com/APICInfectionPreventionandYou). For information on what patients and families can do, visit APIC’s Infection Prevention and You website at [www.apic.org/infectionpreventionandyou](http://www.apic.org/infectionpreventionandyou).

**NOTES FOR EDITORS**


**Authors:**

L. Silvia Munoz-Price, MD, PhD (Corresponding Author)  
Dept of Medicine, University of Miami Miller School of Medicine, Miami, FL